Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...
The European Commission has granted marketing authorisation (MA) for Eli Lilly's ramucirumab (Cyramza) in stomach cancer, making it the first therapy approved for second-line advanced stomach and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback